- VectorBuilder announced plans to build a $500 million gene delivery manufacturing and research campus in Guangzhou.
- Bayer announced China approval of Vitrakvi™ (larotrectinib), a precision medicine for adult and pediatric patients who have advanced solid tumors that harbor a Neurotrophic Tyrosine Receptor Kinase (NTRK) gene fusion.
- Shanghai Junshi Bio was granted US Orphan Drug Designation for toripalimab, its PD-1 inhibitor, to treat small cell lung cancer.
For further details see:
Week In Review: VectorBuilder Plans $500 Million Gene Therapy Delivery CDMO In Guangzhou